Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
0.6926
+0.0174 (2.58%)
At close: Apr 7, 2026, 4:00 PM EDT
0.6705
-0.0221 (-3.19%)
After-hours: Apr 7, 2026, 7:23 PM EDT
Genenta Science Employees
Genenta Science had 13 employees as of December 31, 2024. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$589,755
Market Cap
16.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | -1 | -7.14% |
| Dec 31, 2023 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cue Biopharma | 29 |
| Lantern Pharma | 24 |
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 19 |
| Lipocine | 14 |
| Allarity Therapeutics | 7 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
GNTA News
- 11 days ago - Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs - GlobeNewsWire
- 14 days ago - Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini - GlobeNewsWire
- 25 days ago - Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University - GlobeNewsWire
- 5 weeks ago - Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform - GlobeNewsWire
- 2 months ago - Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments - Benzinga
- 2 months ago - Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator - GlobeNewsWire
- 3 months ago - Genenta Science Provides Update on CEO Ownership - GlobeNewsWire
- 4 months ago - Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewsWire